According to Yifan Pharmaceutical's announcement, Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” issued by the State Drug Administration for the registration and marketing of isazomi citrate capsules. The drug is a class of 4 chemicals with specifications of 2.3 mg, 3 mg, and 4 mg. It is used in combination with lenalidomide and dexamethasone to treat adult patients with multiple myeloma who have received at least one previous treatment. As of the date of disclosure of the announcement, only 2 domestic companies have listed the drug, and 2 other companies are in the process of applying for listing; the company has invested a total of about 176.24,300 yuan in research and development of the drug's raw materials and formulations. There is uncertainty about the results of the subsequent review and approval of the drug and the sales situation.

According to Yifan Pharmaceutical's announcement, Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Notice of Acceptance” issued by the State Drug Administration for the registration and marketing of isazomi citrate capsules. The drug is a class of 4 chemicals with specifications of 2.3 mg, 3 mg, and 4 mg. It is used in combination with lenalidomide and dexamethasone to treat adult patients with multiple myeloma who have received at least one previous treatment. As of the date of disclosure of the announcement, only 2 domestic companies have listed the drug, and 2 other companies are in the process of applying for listing; the company has invested a total of about 176.24,300 yuan in research and development of the drug's raw materials and formulations. There is uncertainty about the results of the subsequent review and approval of the drug and the sales situation.